undamentalytics Newsletter
Sign in

Bluejay Diagnostics, Inc. key statistics and ratios

In fiscal 2022, Bluejay Diagnostics, Inc. had return on equity of -80.6% and a net margin of -3733.1%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 2022
Net margin<−999%
Return on equity−80.6%
Return on assets−68.8%
R&D as % of revenue>999%
SG&A as % of revenue181.3%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Bluejay Diagnostics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bluejay Diagnostics, Inc.